Cardiovascular Clinical Trials with Patient Diversity: Challenges and Considerations
XTalks
AUGUST 4, 2022
This started back in 1993 when the FDA established guidelines to increase diversity by gender and race/ethnicity of participants in clinical trials that were contributing to new drug approvals. An analysis of trials that supported FDA approvals of new cardiometabolic drugs from 2008 to 2017.
52 
Let's personalize your content